Cellectis SA
PAR:ALCLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cellectis SA
PAR:ALCLS
|
FR |
|
XPS Pensions Group PLC
LSE:XPS
|
UK |
|
H
|
Heeton Holdings Ltd
SWB:SST
|
SG |
|
T
|
Touax Sgtr Cite Sgt Cmte Taf Slm Touage Investissements Reunies SCA
PAR:TOUP
|
FR |
|
X
|
XBP Europe Holdings Inc
NASDAQ:XBP
|
US |
|
Samwha Electric Co Ltd
KRX:009470
|
KR |
|
Walkabout Resources Ltd
ASX:WKT
|
AU |
|
Liquidia Corp
NASDAQ:LQDA
|
US |
|
DX (Group) PLC
LSE:DX
|
UK |
|
S
|
SBFC Finance Ltd
BSE:543959
|
IN |
Cellectis SA
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Cellectis SA engages as a biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. The company is headquartered in Paris, Ile-De-France and currently employs 345 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Clinical win: lasme-cel (CD22) showed strong Phase I signals — 83% ORR at the recommended Phase II dose and 100% ORR in the target Phase II population — and converted all target patients to transplant-eligible status.
Pivotal timing: First interim analysis of the lasme-cel pivotal Phase II (40 patients) expected Q4 2026; BLA submission targeted H2 2028.
Another promising asset: eti-cel (dual CD20/CD22) reported an 88% ORR and 63% CR in early data; full Phase I data (including low‑dose IL-2 cohort) expected later in 2026 and pivotal start planned in 2027.
Manufacturing edge: Internally manufactured lasme-cel performed better than externally made product in Phase I (68% vs 28% ORR), supporting Cellectis' decision to internalize manufacturing.
Cash runway: Cash, cash equivalents, restricted cash and fixed term deposits were $211 million as of December 31, 2025, sufficient to fund operations into H2 2027 per management.
Partnership catalysts: Servier/Allogene cema-cel interim futility analysis on track for Q2 2026; Iovance IOV-4001 readout expected in 2026; collaboration with AstraZeneca ongoing (up to 10 programs).
Arbitration outcome: UCART19/ALLO-501 returned to Cellectis; arbitral decision did not affect cema-cel and Cellectis remains eligible for up to $340 million in Servier/Allogene milestones.
Safety profile: lasme-cel had low rates of high-grade neurotoxicity and CRS (Grade ≥3 CRS 2.5%, Grade ≥3 ICANS 5% at the RP2D).
